| Abstract |
We developed a novel effective experimental therapy for inflammatory diseases, by using, genetically modified bacteria, Lactococcus lactis that synthesize and secrete very low doses of antigen (protein) at the site of the intestinal mucosa thereby inducing antigen-specific tolerance. This approach has been shown to be very effective in the preclinical setting and offers a great opportunity for further development as a therapy for mucosal and systemic autoimmune, inflammatory and/or allergic diseases.
|
